Steven H. Liang

Dr. Steven H. Liang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2016 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MFMinghao Feng
Minghao Feng
BTBingqing Tang
Bingqing Tang
SLSteven H. Liang
Steven H. Liang
XJXuefeng Jiang
Xuefeng Jiang
The impact of the development of sulfur therapeutics is instrumental to the evolution of the pharmaceutical industry. Sulfur-derived functional groups can be found in a broad range of pharmaceuticals and natural products. For centuries, sulfur continues to maintain its status as the dominating heteroatom integrated into a set of 362 sulfur-containing FDA approved drugs (besides oxygen or nitrogen) through the present. Sulfonamides, thioethers, sulfones and Penicillin are the most common scaffolds in sulfur containing drugs, which are well studied both on synthesis and application during the past decades. In this review, these four moieties in pharmaceuticals and recent advances in the synthesis of the corresponding core scaffolds are presented.

14 January 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
XDXiaoyun Deng
Xiaoyun Deng
JRJian Rong
Jian Rong
LWLu Wang
Lu Wang
NVNeil Vasdev
Neil Vasdev
LZLei Zhang
Lei Zhang
SLSteven H. Liang
Steven H. Liang

8 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKuan Hu
Kuan Hu
LXLin Xie
Lin Xie
YZYiding Zhang
Yiding Zhang
MHMasayuki Hanyu
Masayuki Hanyu
ZYZhimin Yang
Zhimin Yang
MZMing-Rong Zhang
Ming-Rong Zhang
The use of photothermal agents (PTAs) in cancer photothermal therapy (PTT) has shown promising results in clinical studies. The rapid degradation of PTAs may address safety concerns but usually limits the photothermal stability required for efficacious treatment. Conversely, PTAs with high photothermal stability usually degrade slowly. The solutions that address the balance between the high photothermal stability and rapid degradation of PTAs are rare. Here, we report that the inherent Cu2+-capturing ability of black phosphorus (BP) can accelerate the degradation of BP, while also enhancing photothermal stability. The incorporation of Cu2+into BP@Cu nanostructures further enables chemodynamic therapy (CDT)-enhanced PTT. Moreover, by employing64Cu2+, positron emission tomography (PET) imaging can be achieved for in vivo real-time and quantitative tracking. Therefore, our study not only introduces an “ideal” PTA that bypasses the limitations of PTAs, but also provides the proof-of-concept application of BP-based materials in PET-guided, CDT-enhanced combination cancer therapy.

5 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JRJian Rong
Jian Rong
AHAhmed Haider
Ahmed Haider
TJTroels Jeppesen
Troels Jeppesen
LJLee Josephson
Lee Josephson
SLSteven H. Liang
Steven H. Liang
Positron emission tomography (PET) constitutes a functional imaging technique that is harnessed to probe biological processes in vivo. PET imaging has been used to diagnose and monitor the progression of diseases, as well as to facilitate drug development efforts at both preclinical and clinical stages. The wide applications and rapid development of PET have ultimately led to an increasing demand for new methods in radiochemistry, with the aim to expand the scope of synthons amenable for radiolabeling. In this work, we provide an overview of commonly used chemical transformations for the syntheses of PET tracers in all aspects of radiochemistry, thereby highlighting recent breakthrough discoveries and contemporary challenges in the field. We discuss the use of biologicals for PET imaging and highlight general examples of successful probe discoveries for molecular imaging with PET – with a particular focus on translational and scalable radiochemistry concepts that have been entered to clinical use.

1 February 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
LZLingling Zhang
Lingling Zhang
Kuan HuKuan Hu
Kuan Hu
TSTuo Shao
Tuo Shao
LHLu Hou
Lu Hou
SZShaojuan Zhang
Shaojuan Zhang
SLSteven H. Liang
Steven H. Liang
The 18 kDa translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor, is predominately localized to the outer mitochondrial membrane in steroidogenic cells. Brain TSPO expression is relatively low under physiological conditions, but is upregulated in response to glial cell activation. As the primary index of neuroinflammation, TSPO is implicated in the pathogenesis and progression of numerous neuropsychiatric disorders and neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), multiple sclerosis (MS), major depressive disorder (MDD) and obsessive compulsive disorder (OCD). In this context, numerous TSPO-targeted positron emission tomography (PET) tracers have been developed. Among them, several radioligands have advanced to clinical research studies. In this review, we will overview the recent development of TSPO PET tracers, focusing on the radioligand design, radioisotope labeling, pharmacokinetics, and PET imaging evaluation. Additionally, we will consider current limitations, as well as translational potential for future application of TSPO radiopharmaceuticals. This review aims to not only present the challenges in current TSPO PET imaging, but to also provide a new perspective on TSPO targeted PET tracer discovery efforts. Addressing these challenges will facilitate the translation of TSPO in clinical studies of neuroinflammation associated with central nervous system diseases.

21 September 2015 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JZJian Zheng
Jian Zheng
LWLu Wang
Lu Wang
JLJin‐Hong Lin
Jin‐Hong Lin
JXJichang Xiao
Jichang Xiao
SLSteven H. Liang
Steven H. Liang